Stock Analysis

3 Stocks Estimated To Be Trading Below Intrinsic Value By 18.1% To 25.2%

Published

As global markets experience broad-based gains with U.S. indexes nearing record highs, investor sentiment is buoyed by strong labor market data and positive home sales reports. In this environment of cautious optimism, identifying undervalued stocks can be a strategic move for investors looking to capitalize on potential growth opportunities.

Top 10 Undervalued Stocks Based On Cash Flows

NameCurrent PriceFair Value (Est)Discount (Est)
Shenzhen King Explorer Science and Technology (SZSE:002917)CN¥9.60CN¥18.8249%
NBT Bancorp (NasdaqGS:NBTB)US$50.08US$99.9349.9%
HangzhouS MedTech (SHSE:688581)CN¥63.94CN¥124.1648.5%
Nordic Waterproofing Holding (OM:NWG)SEK172.40SEK344.2749.9%
Insyde Software (TPEX:6231)NT$466.50NT$923.5049.5%
Power Root Berhad (KLSE:PWROOT)MYR1.46MYR2.9250%
EnomotoLtd (TSE:6928)¥1472.00¥2935.4249.9%
DUG Technology (ASX:DUG)A$1.67A$3.4050.8%
Intermedical Care and Lab Hospital (SET:IMH)THB4.94THB9.8649.9%
Audinate Group (ASX:AD8)A$8.83A$17.5449.7%

Click here to see the full list of 912 stocks from our Undervalued Stocks Based On Cash Flows screener.

Let's dive into some prime choices out of the screener.

Hwatsing Technology (SHSE:688120)

Overview: Hwatsing Technology Co., Ltd. is a Chinese company that manufactures semiconductor equipment products and has a market cap of approximately CN¥44.14 billion.

Operations: The company's revenue from semiconductor equipment and services amounts to CN¥3.12 billion.

Estimated Discount To Fair Value: 18.1%

Hwatsing Technology is trading at CN¥189.46, below its estimated fair value of CN¥231.38, indicating potential undervaluation based on cash flows. The company reported strong earnings growth with net income rising to CN¥720.7 million for the nine months ending September 2024, compared to CN¥563.93 million a year ago. Earnings are forecast to grow significantly at 27.1% annually, outpacing market expectations despite recent share price volatility and modest buyback activities.

SHSE:688120 Discounted Cash Flow as at Nov 2024

Xiamen Amoytop Biotech (SHSE:688278)

Overview: Xiamen Amoytop Biotech Co., Ltd. is involved in the manufacture, marketing, and sale of recombinant protein drugs in China, with a market cap of CN¥29.92 billion.

Operations: The company's revenue is primarily generated from its biologics segment, amounting to CN¥2.60 billion.

Estimated Discount To Fair Value: 22.7%

Xiamen Amoytop Biotech is trading at CN¥74.5, significantly below its estimated fair value of CN¥96.38, suggesting it may be undervalued based on cash flows. The company reported robust growth with sales reaching CN¥1.95 billion and net income rising to CN¥554.15 million for the nine months ending September 2024, compared to the previous year. Earnings are projected to grow substantially at 32% annually, surpassing market averages despite a low dividend coverage by free cash flows.

SHSE:688278 Discounted Cash Flow as at Nov 2024

Geovis TechnologyLtd (SHSE:688568)

Overview: Geovis Technology Co., Ltd focuses on the research, development, and industrialization of digital earth products for various sectors in China, with a market cap of CN¥31.85 billion.

Operations: Geovis Technology Co., Ltd's revenue is derived from its digital earth products tailored for government, enterprise, and public sectors in China.

Estimated Discount To Fair Value: 25.2%

Geovis Technology Ltd. is trading at CN¥59.58, well below its estimated fair value of CN¥79.7, indicating potential undervaluation based on cash flows. The company posted strong financial performance with sales of CNY 2 billion and net income of CNY 145.68 million for the nine months ending September 2024, showing significant growth from the previous year. Earnings are forecast to grow substantially at 37% annually, outpacing market averages despite recent share price volatility.

SHSE:688568 Discounted Cash Flow as at Nov 2024

Key Takeaways

Looking For Alternative Opportunities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Hwatsing Technology might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com